A detailed history of Woodline Partners LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Woodline Partners LP holds 516,379 shares of CNTA stock, worth $9.04 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
516,379
Previous 123,461 318.25%
Holding current value
$9.04 Million
Previous $1.11 Million 641.11%
% of portfolio
0.07%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.58 - $16.99 $3.37 Million - $6.68 Million
392,918 Added 318.25%
516,379 $8.26 Million
Q2 2024

Aug 14, 2024

BUY
$8.04 - $11.87 $992,626 - $1.47 Million
123,461 New
123,461 $1.11 Million
Q4 2023

Feb 14, 2024

SELL
$5.52 - $8.03 $382,800 - $556,864
-69,348 Reduced 32.99%
140,856 $1.12 Million
Q3 2023

Nov 14, 2023

SELL
$6.01 - $8.24 $2.87 Million - $3.94 Million
-477,559 Reduced 69.44%
210,204 $1.36 Million
Q2 2023

Aug 14, 2023

SELL
$3.68 - $6.9 $177,486 - $332,787
-48,230 Reduced 6.55%
687,763 $4.26 Million
Q1 2023

May 15, 2023

BUY
$3.03 - $4.0 $1.57 Million - $2.07 Million
516,573 Added 235.43%
735,993 $2.83 Million
Q4 2022

Feb 14, 2023

BUY
$3.05 - $4.19 $124,598 - $171,169
40,852 Added 22.88%
219,420 $680,000
Q3 2022

Nov 14, 2022

SELL
$3.8 - $5.91 $4.32 Million - $6.71 Million
-1,136,084 Reduced 86.42%
178,568 $718,000
Q2 2022

Aug 15, 2022

BUY
$3.18 - $9.85 $1.37 Million - $4.26 Million
432,019 Added 48.95%
1,314,652 $6.4 Million
Q1 2022

May 16, 2022

BUY
$7.45 - $11.59 $607,152 - $944,550
81,497 Added 10.17%
882,633 $7.92 Million
Q4 2021

Feb 14, 2022

SELL
$10.99 - $17.54 $897,630 - $1.43 Million
-81,677 Reduced 9.25%
801,136 $9.02 Million
Q3 2021

Nov 15, 2021

BUY
$16.7 - $23.11 $1.01 Million - $1.39 Million
60,295 Added 7.33%
882,813 $14.7 Million
Q2 2021

Aug 16, 2021

BUY
$21.71 - $25.66 $17.9 Million - $21.1 Million
822,518 New
822,518 $18.3 Million

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.65B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.